Skip to main content
SpringerLink
Log in

Neue Therapien beim systemischen Lupus erythematodes

New treatments for systemic lupus erythematosus

  • Leitthema
  • Published:
Zeitschrift für Rheumatologie Aims and scope Submit manuscript

Zusammenfassung

Ein verbessertes Verständnis der Pathomechanismen, die zur Entstehung des systemischen Lupus erythematodes (SLE) beitragen, haben in Analogie zu Erkrankungen wie der rheumatoiden Arthritis und den Spondylarthritiden auch zu neuen selektiven Therapiestrategien bei dieser entzündlichen Systemerkrankung geführt. Neue, spezifische Biologika wurden entwickelt oder sind in der Entwicklung und eröffnen neue Therapieoptionen für unsere Patienten. In diesem Zusammenhang ist v. a. Belimumab zu nennen. Der Antikörper gegen das Zytokin BAFF („B cell activating factor“)/BLyS („B lymphocyte stimulator“) ist das erste zugelassene Medikament für die Therapie des SLE in den letzten Jahrzehnten und zugleich das erste für diese Erkrankung zugelassene Biologikum. Andere Medikamente zur Behandlung von SLE-Patienten sind in der klinischen Entwicklung. Hier soll es in erster Linie um die in der Entwicklung befindlichen neuen Medikamente in der Therapie des SLE gehen.

Abstract

Improved understanding of the immunopathogenesis of systemic lupus erythematosus (SLE) has paved the way for new selective treatment strategies for these inflammatory systemic diseases, similarly to diseases such as rheumatoid arthritis and the spondylarthritides. New specific biologics were developed or are being developed and open up new treatment options for patients. Belimumab is particularly important in this respect. The monoclonal antibody that blocks the cytokine BAFF/BLyS is the first medicament approved for the treatment of serologically active SLE in the last decade and also the first biologic approved for this disease. A number of other biologics for the treatment of SLE are in clinical development. This article addresses the promising new drugs currently under development for the treatment of SLE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Urowitz MB et al (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24(6):1061–1065

    CAS  PubMed  Google Scholar 

  2. Hahn BH (1998) Antibodies to DNA. N Engl J Med 338(19):1359–1368

    Article  CAS  PubMed  Google Scholar 

  3. Diaz-Lagares C et al (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11(5):357–364

    Article  CAS  PubMed  Google Scholar 

  4. Ezeonyeji AN, Isenberg DA (2012) Early treatment with rituximab in newly diagnosed systemic lupus erythematosus patients: a steroid-sparing regimen. Rheumatology 51(3):476–481

    Article  CAS  PubMed  Google Scholar 

  5. Lu TY et al (2009) A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 61(4):482–487

    Article  PubMed  Google Scholar 

  6. Rovin BH et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64(4):1215–1226

    Article  CAS  PubMed  Google Scholar 

  7. Murray E, Perry M (2010) Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol 29(7):707–716

    Article  PubMed  PubMed Central  Google Scholar 

  8. Fanouriakis A et al (2019) 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis 78(6):736–745

    Article  CAS  PubMed  Google Scholar 

  9. Kraaij T et al (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45–54

    Article  CAS  PubMed  Google Scholar 

  10. Condon MB et al (2013) Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 72(8):1280–1286

    Article  CAS  PubMed  Google Scholar 

  11. Mysler EF et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65(9):2368–2379

    Article  CAS  PubMed  Google Scholar 

  12. Freeman CL, Sehn LH (2018) A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol 182(1):29–45

    Article  PubMed  Google Scholar 

  13. Furie R et al (2019) A phase II randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of obinutuzumab or placebo in combination with Mycophenolate Mofetil in patients with active class III or IV lupus nephritis. Arthritis Rheumatol 71:Abstract ACR

  14. Dorner T, Lipsky PE (2014) B cells: depletion or functional modulation in rheumatic diseases. Curr Opin Rheumatol 26(2):228–236

    Article  PubMed  Google Scholar 

  15. Mok CC, Lau CS (2003) Pathogenesis of systemic lupus erythematosus. J Clin Pathol 56(7):481–490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hiepe F et al (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170–178

    Article  CAS  PubMed  Google Scholar 

  17. Dorner T, Kinnman N, Tak PP (2010) Targeting B cells in immune-mediated inflammatory disease: a comprehensive review of mechanisms of action and identification of biomarkers. Pharmacol Ther 125(3):464–475

    Article  PubMed  CAS  Google Scholar 

  18. Hoyer BF et al (2004) Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 199(11):1577–1584

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pena-Rossi C et al (2009) An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 18(6):547–555

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ginzler EM et al (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14(1):R33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Isenberg D et al (2014) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2013-205067

    Article  PubMed  PubMed Central  Google Scholar 

  22. Gordon C et al (2014) Effects of Atacicept on disease activity in patients witch moderate to severe systemic lupus erythematosus: APRIL-SLE randomized trial. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2014-eular.4384

    Article  PubMed  PubMed Central  Google Scholar 

  23. Cheng Q et al (2020) Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies. Eur J Immunol 50(2):284–291

    Article  CAS  PubMed  Google Scholar 

  24. Inghirami G et al (1988) Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol 6(3):269–276

    CAS  PubMed  Google Scholar 

  25. Larosa M et al (2019) IL-12 and IL-23/Th17 axis in systemic lupus erythematosus. Exp Biol Med 244(1):42–51

    Article  CAS  Google Scholar 

  26. Moreland LW et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 46(6):1470–1479

    Article  CAS  PubMed  Google Scholar 

  27. Merrill JT et al (2010) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62(10):3077–3087

    Article  CAS  PubMed  Google Scholar 

  28. Furie R et al (2014) Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 66(2):379–389

    Article  CAS  PubMed  Google Scholar 

  29. Danion F et al (2016) Efficacy of abatacept in systemic lupus erythematosus: a retrospective analysis of 11 patients with refractory disease. Lupus 25(13):1440–1447

    Article  CAS  PubMed  Google Scholar 

  30. Kalunian KC et al (2002) Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 46(12):3251–3258

    Article  CAS  PubMed  Google Scholar 

  31. Liossis SN, Sfikakis PP (2004) Costimulation blockade in the treatment of rheumatic diseases. BioDrugs 18(2):95–102

    Article  CAS  PubMed  Google Scholar 

  32. Furie R et al (2019) FRI0195 efficacy and safety of dapirolizumab pegol (DZP) in patients with moderately TO severely active systemic lupus Erythematosus (SLE): a randomised, placebo (PBO)-controlled study. Ann Rheum Dis 78(Suppl 2):775–776

    Google Scholar 

  33. Humrich JY, Riemekasten G (2016) IL-2-therapy in SLE- selective reconstitution of immunological tolerance. Z Rheumatol 75(5):490–492

    Article  CAS  PubMed  Google Scholar 

  34. Humrich J et al (2019) Low-dose interleukin‑2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial. Lancet Rheumatol 1(1):E44–E54

    Article  Google Scholar 

  35. Huang X et al (2007) Dysregulated expression of interleukin-23 and interleukin-12 subunits in systemic lupus erythematosus patients. Mod Rheumatol 17(3):220–223

    Article  CAS  PubMed  Google Scholar 

  36. Ball EM et al (2014) Plasma IL‑6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus 23(1):46–56

    Article  CAS  PubMed  Google Scholar 

  37. Ripley BJ et al (2005) Raised levels of interleukin 6 in systemic lupus erythematosus correlate with anaemia. Ann Rheum Dis 64(6):849–853

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Tsai CY et al (2000) Increased excretions of beta2-microglobulin, IL‑6, and IL‑8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85(3):207–214

    Article  CAS  PubMed  Google Scholar 

  39. Illei GG et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542–552

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Shirota Y et al (2013) Impact of anti-interleukin‑6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 72(1):118–128

    Article  CAS  PubMed  Google Scholar 

  41. Rovin BH, Vollenhoven RF van, Aranow C, Wagner C, Gordon R, Zhuang Y et al (2016) A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis Rheumatol 68(9):2174–2183. https://doi.org/10.1002/art.39722

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Rose T et al (2013) IFNalpha and its response proteins, IP-10 and SIGLEC‑1, are biomarkers of disease activity in systemic lupus erythematosus. Ann Rheum Dis 72(10):1639–1645

    Article  CAS  PubMed  Google Scholar 

  43. McBride JM et al (2012) Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum 64(11):3666–3676

    Article  CAS  PubMed  Google Scholar 

  44. Petri M et al (2013) Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study. Arthritis Rheum 65(4):1011–1021

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Morand EF et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382(3):211–221

    Article  CAS  PubMed  Google Scholar 

  46. Werth VP, Merrill JT (2019) A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Br J Dermatol 180(5):964–965

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin I, Rheumatologie/klinische Immunologie und Exzellenzzentrum Entzündungsmedizin, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Arnold-Heller-Str. 3, 24105, Kiel, Deutschland

    Bimba F. Hoyer

Authors
  1. Bimba F. Hoyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bimba F. Hoyer.

Ethics declarations

Interessenkonflikt

B.F. Hoyer gibt an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

Redaktion

B.F. Hoyer, Kiel

H.-M. Lorenz, Heidelberg

M. Schneider, Düsseldorf

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoyer, B.F. Neue Therapien beim systemischen Lupus erythematodes. Z Rheumatol 79, 342–350 (2020). https://doi.org/10.1007/s00393-020-00788-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00393-020-00788-1

Schlüsselwörter

Keywords

Search

Navigation